GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (NAS:ANL) » Definitions » Capex-to-Revenue

ANL (Adlai Nortye) Capex-to-Revenue : 0.00 (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Adlai Nortye Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Adlai Nortye's Capital Expenditure for the three months ended in Jun. 2024 was $0.00 Mil. Its Revenue for the three months ended in Jun. 2024 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.

Adlai Nortye Capex-to-Revenue Historical Data

The historical data trend for Adlai Nortye's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adlai Nortye Capex-to-Revenue Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23
Capex-to-Revenue
0.02 - 0.04

Adlai Nortye Quarterly Data
Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23 Jun24
Capex-to-Revenue Get a 7-Day Free Trial - - - - -

Competitive Comparison of Adlai Nortye's Capex-to-Revenue

For the Biotechnology subindustry, Adlai Nortye's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adlai Nortye's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adlai Nortye's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Adlai Nortye's Capex-to-Revenue falls into.


;
;

Adlai Nortye Capex-to-Revenue Calculation

Adlai Nortye's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.2) / 5
=0.04

Adlai Nortye's Capex-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adlai Nortye  (NAS:ANL) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Adlai Nortye Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Adlai Nortye's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Adlai Nortye Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (NAS:ANL) » Definitions » Capex-to-Revenue
Comparable Companies
ABOS IVVD CLSD MNOV AVTE ACRV NTRB EPIX IGMS DOMH VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
685 US Highway 1, New Jersey Biotechnology Development Center, 2nd floor, North Brunswick, NJ, USA, 08902
Website
https://www.adlainortye.com
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.